Supplementary Table S3 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype

Supplementary Table S3 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype

<p>Supplementary Table S3 shows the Phospho GENE report</p>

Gorde:

Xehetasun bibliografikoak
Egile nagusia:	Fleur M.G. Cornelissen (22761190) (author)
Beste egile batzuk:	Yoran Broersma (22761193) (author), Ravi S. Narayan (22761196) (author), Rogier Dik (22761199) (author), Sander R. Piersma (22761202) (author), Richard de Goeij-de Haas (22761205) (author), Thang V. Pham (15037293) (author), David Noske (18366693) (author), William P. Vandertop (15037296) (author), Connie R. Jimenez (12057149) (author), Bart A. Westerman (18100116) (author)
Argitaratua:	2025
Gaiak:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Cell Signaling Phosphatases CNS Cancers Gliomas, Glioblastomas Drug Resistance Drug Targets Metabolism Metabolic pathways
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak

Supplementary Figure S1 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Figure S2 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Figure S3 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Figure S4 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Figure S5 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Figure S6 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Figure S7 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Figure S8 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Table S1 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Table S2 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Table S4 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Table S5 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Table S6 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Table S7 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Table S8 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
nork: Fleur M.G. Cornelissen (22761190)
Argitaratua: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
nork: Sied Kebir (15048732)
Argitaratua: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
nork: Sied Kebir (15048732)
Argitaratua: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
nork: Sied Kebir (15048732)
Argitaratua: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
nork: Sied Kebir (15048732)
Argitaratua: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
nork: Sied Kebir (15048732)
Argitaratua: (2025)

Supplementary Table S1 from Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress
nork: Jianpeng Yu (22435975)
Argitaratua: (2025)

Supplementary Figure 1 from Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood–Brain Barrier Opening
nork: Karl J. Habashy (17801087)
Argitaratua: (2025)

Supplementary Figure 2 from Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood–Brain Barrier Opening
nork: Karl J. Habashy (17801087)
Argitaratua: (2025)

Supplementary Figure 3 from Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood–Brain Barrier Opening
nork: Karl J. Habashy (17801087)
Argitaratua: (2025)

Figure 1 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
nork: Elisa Izquierdo (15110795)
Argitaratua: (2025)

Figure 2 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
nork: Elisa Izquierdo (15110795)
Argitaratua: (2025)

Figure 3 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
nork: Elisa Izquierdo (15110795)
Argitaratua: (2025)

Figure 4 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
nork: Elisa Izquierdo (15110795)
Argitaratua: (2025)

Figure 5 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
nork: Elisa Izquierdo (15110795)
Argitaratua: (2025)

Figure 6 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
nork: Elisa Izquierdo (15110795)
Argitaratua: (2025)

Figure 7 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
nork: Elisa Izquierdo (15110795)
Argitaratua: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
nork: Anne-Florence Blandin (15056366)
Argitaratua: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
nork: Anne-Florence Blandin (15056366)
Argitaratua: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
nork: Anne-Florence Blandin (15056366)
Argitaratua: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
nork: Anne-Florence Blandin (15056366)
Argitaratua: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
nork: Anne-Florence Blandin (15056366)
Argitaratua: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
nork: Anne-Florence Blandin (15056366)
Argitaratua: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
nork: Anne-Florence Blandin (15056366)
Argitaratua: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
nork: William Kelly (15439117)
Argitaratua: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
nork: William Kelly (15439117)
Argitaratua: (2025)